Publications

• Distal splenorenal and mesocaval shunting at the time of pancreatectomy.

  (Chavez MI, Tsai S, Clarke CN, Aldakkak M, Griffin MO, Khan AH, Ritch PS, Erickson BA, Evans DB, Christians KK.) Surgery. 2019 Feb;165(2):298-306.

• Patients with Oncocytic Variant Papillary Thyroid Carcinoma Have a Similar Prognosis to Matched Classical Papillary Thyroid Carcinoma Controls.

  (Carr AA, Yen TWF, Ortiz DI, Hunt BC, Fareau G, Massey BL, Campbell BH, Doffek KL, Evans DB, Wang TS.) Thyroid. 2018 11;28(11):1462-1467.

• Importance of Normalization of CA19-9 Levels Following Neoadjuvant Therapy in Patients With Localized Pancreatic Cancer.

  (Tsai S, George B, Wittmann D, Ritch PS, Krepline AN, Aldakkak M, Barnes CA, Christians KK, Dua K, Griffin M, Hagen C, Hall WA, Erickson BA, Evans DB.) Ann Surg. 2018 Oct 11.

• A Phase II Clinical Trial of Molecular Profiled Neoadjuvant Therapy for Localized Pancreatic Ductal Adenocarcinoma.

  (Tsai S, Christians KK, George B, Ritch PS, Dua K, Khan A, Mackinnon AC, Tolat P, Ahmad SA, Hall WA, Erickson BA, Evans DB.) Ann Surg. 2018 Oct;268(4):610-619.

• A postoperative parathyroid hormone-based algorithm to reduce symptomatic hypocalcemia following completion/total thyroidectomy: A retrospective analysis of 591 patients.

  (Mazotas IG, Yen TWF, Park J, Liu Y, Eastwood DC, Carr AA, Evans DB, Wang TS.) Surgery. 2018 10;164(4):746-753.

• Prophylactic Central Compartment Neck Dissection in Papillary Thyroid Cancer and Effect on Locoregional Recurrence.

  (Hughes DT, Rosen JE, Evans DB, Grubbs E, Wang TS, Solórzano CC.) Ann Surg Oncol. 2018 Sep;25(9):2526-2534.

• Molecular evaluation of a sporadic paraganglioma with concurrent IDH1 and ATRX mutations.

  (Zhang J, Jiang J, Luo Y, Li X, Lu Z, Liu Y, Huang J, Hou Y, Pang Y, Sun MYF, Wang TS, Evans DB, Pacak K, Zhuang Z, Gao X.) Endocrine. 2018 08;61(2):216-223.

• Thyroid cancer in adolescents and young adults.

  (Massimino M, Evans DB, Podda M, Spinelli C, Collini P, Pizzi N, Bleyer A.) Pediatr Blood Cancer. 2018 Aug;65(8):e27025.

• What Makes a Pancreatic Cancer Resectable?

  (Evans DB.) Am Soc Clin Oncol Educ Book. 2018 May 23;38:300-305.

• Locally advanced pancreas cancer: Staging and goals of therapy.

  (Chatzizacharias NA, Tsai S, Griffin M, Tolat P, Ritch P, George B, Barnes C, Aldakkak M, Khan AH, Hall W, Erickson B, Evans DB, Christians KK.) Surgery. 2018 05;163(5):1053-1062.

• Development of primary human pancreatic cancer organoids, matched stromal and immune cells and 3D tumor microenvironment models.

  (Tsai S, McOlash L, Palen K, Johnson B, Duris C, Yang Q, Dwinell MB, Hunt B, Evans DB, Gershan J, James MA.) BMC Cancer. 2018 03 27;18(1):335.

• Decreased trend in hospital mortality from pancreatic cancer despite increase in number of hospital admissions.

  (Bhandari S, Abdul MKM, Hollabaugh W, Sharma K, Evans DB, Guda N.) PLoS One. 2018;13(7):e0199909.